Merck & Co., Inc.

Q3 2026
Speakers

Oct 29, 2026 · 61 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Welcome to the Merck and Co. Increase by New Jersey USA third quarter sales and earnings conference call. At this time, all participants are in a listen-only mode until the question and answer session of that time to ask a question, press star one on your phone and record your name at the prompt. This call is being recorded. If you have any objections, you may just time.

I would now like to turn the call over to Mr. Peter Danenbaum, Senior Vice President, Investor Relations. Sir, you may begin.

Passages & reports (2)
  • Welcome to the Merck and Co. Increase by New Jersey USA third quarter sales and earnings c…
  • call is being recorded. If you have any objections, you may just time. I would now like to…

Speaker 1

Unverified voice label

Thank you, Julie, and good morning, everyone. Welcome to the third quarter 2026 conference call for Merck and Company Incorporated, Railway, New Jersey, USA. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer, Caroline Litchfield, Chief Financial Officer, and Dr. Dean Lee, President of Research Labs. Before we get started, I'd like to point out that we have items in our GAP results, such as acquisition-related charges, restructuring costs, and certain other items that we have excluded from our non-GAAP results.

There is a reconciliation in our press release. I will also remind you that some of the statements that we make today may be considered
forward-looking statements within the meaning of the Safe Harbor Provision of the U.S. Private Securities Litigation Reform Act of nineteen ninety-five. Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties.

If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ
materially from those set forth in the forward looking statements. Our SEC filings, including Item 1A and the 2025 10K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward looking statements made this morning. Merck and Company Incorporated Radway, New Jersey, USA, undertakes no obligation to publicly update any forward looking statements.

During today's call, a slide presentation will accompany our speakers' prepared remarks. These slides, along with the earnings release, today's prepared remarks, and our SEC filings are all posted to the investor relations section of our company's website. With that,
I'd like to turn the call over to Rob. Thank you, Peter.

Passages & reports (6)
  • Thank you, Julie, and good morning, everyone. Welcome to the third quarter 2026 conference…
  • like to point out that we have items in our GAP results, such as acquisition-related charg…
  • forward-looking statements within the meaning of the Safe Harbor Provision of the U.S. Pri…
  • materially from those set forth in the forward looking statements. Our SEC filings, includ…
  • New Jersey, USA, undertakes no obligation to publicly update any forward looking statement…
  • I'd like to turn the call over to Rob. Thank you, Peter.

Speaker 2

Unverified voice label

Good morning, and thank you for joining today's call. 2026 continues to be a year of substantial progress for our company. We're executing well on all fronts. Demonstrated particularly by the many new product launches now successfully underway, and the important clinical milestones we're achieving that are further de-risking the substantial long-term opportunity of our late phase pipeline. This momentum extends across multiple therapeutic areas and modalities, and there is much more to come, with numerous significant readouts still to occur over the coming years.

I'm very pleased that the disciplined execution of our strategy over the past several years is increasingly
translating into meaningful clinical, regulatory, and commercial results. ?The breadth of these achievements strengthens my confidence in the future of our company and our ability to deliver long-term value for patients and shareholders. Turning to our third quarter results, we delivered solid performance with revenue of $18.1 billion, reflecting increased contributions from new products as well as strength in oncology and animal health.

Caroline will discuss our results in the full year outlook in greater detail in a
?moment. We also achieved several important clinical and regulatory milestones. In oncology, last weekend's ESMO meeting showcased potential practice changing advances for several innovative programs highlighted by the first positive phase three results from our expansive global Troy's Fuse program for SAC TMT in advanced or recurrent endometrial cancer. Additional data shared at the meeting from our partner Calloon further support the potential of SAC TMT in lung cancer and other tumor types.

And we are encouraged by the landmark validation of a therapeutic cancer vaccine with positive phase three data presented for entismeron autogene as an adjuvant
treatment for certain patients with melanoma. This new approach may offer a tangible opportunity to change the trajectory of a patient's cancer.

Passages & reports (10)
  • Good morning, and thank you for joining today's call. 2026 continues to be a year of subst…
  • opportunity of our late phase pipeline. This momentum extends across multiple therapeutic …
  • translating into meaningful clinical, regulatory, and commercial results.
  • The
  • breadth of these achievements strengthens my confidence in the future of our company and o…
  • strength in oncology and animal health. Caroline will discuss our results in the full year…
  • moment.
  • We also achieved several important clinical and regulatory milestones. In oncology, last w…
  • endometrial cancer. Additional data shared at the meeting from our partner Calloon further…
  • treatment for certain patients with melanoma. This new approach may offer a tangible oppor…

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 2

ophthalmology, we presented results from the Brunello study evaluating RemigramIG in diabetic macular edema, a significant milestone for our rapidly advancing retinal disease portfolio. And finally, in immunology, we presented encouraging Phase 2B results in HS and look forward to advancing our TL1A development program.

Passages & reports (2)
  • ophthalmology, we presented results from the Brunello study evaluating RemigramIG in diabe…
  • advancing our TL1A development program.

Speaker unclear

?This

Passages & reports (1)
  • This

Speaker 2

year's clinical and commercial progress underlines the ongoing transformation of our business and provides us with greater visibility into the trajectory of our emerging and expansive new product portfolio. The opportunity we have to drive strong long term growth beyond the Katruda LOE period is becoming increasingly clear as we achieve these scientific and commercial milestones. As we look ahead, we'll remain focused on successfully executing our launches, broadening and advancing our pipeline, and making meaningful investments to realize the full potential of these opportunities.

I want to recognize and thank our dedicated global teams for their ongoing
commitment to delivering value for patients, shareholders, and all of our stakeholders. And now I'll turn the call over to Caroline.

Passages & reports (3)
  • year's clinical and commercial progress underlines the ongoing transformation of our busin…
  • achieve these scientific and commercial milestones. As we look ahead, we'll remain focused…
  • commitment to delivering value for patients, shareholders, and all of our stakeholders. An…

Speaker 3

Unverified voice label

Thank you, Rob.

Passages & reports (1)
  • Thank you, Rob.

Speaker unclear

?Good morning.

Passages & reports (1)
  • Good morning.

Speaker 0

As Rob noted,

Passages & reports (1)
  • As Rob noted,

Speaker 3

we delivered solid performance in the quarter,

Passages & reports (1)
  • we delivered solid performance in the quarter,

Speaker 0

driven

Passages & reports (1)
  • driven

Speaker 3

by increasing contributions ?from our compelling array of important new products and continued strength in oncology and animal health. Strong commercial and operational execution continues to propel our near-term performance while we invest to optimise our launches and advance our broad and deep pipeline to create long-term value for patients, customers and shareholders. Now turning to our third quarter results. Total company revenues were $18.1 billion, an increase of 5% or 4%, excluding the impact of foreign exchange.

The following revenue comments will be on an ex
exchange basis. In oncology, sales of the Quetruda family of products, which includes Quetruda and Quetruda Culex, increased 6% to $8.6 billion, with global growth driven by strong uptake in earlier stage cancers and continued robust demand for metastatic indications. Key contributors to growth included strong utilization in tumours that primarily affect women, particularly cervical and breast cancers, as well as increased use of keytruder plus PADCEF in urethelial cancer.

We also saw continued uptake in earlier
stage head and neck cancer. As expected, the timing of US customer purchases last year created a headwind to growth, but this was largely offset by an increase in channel inventory, which we expect to unwind in the fourth quarter. Sales of Ketruda Culex were $830 million. We continue to see adoption increase, which supports our confidence in the trajectory of the product. ?

In
our broader oncology portfolio, Welly Reg sales increased 58% to $307 million, driven by increased use in previously treated patients and as adjuvant treatment for certain patients with renal cell carcinoma in the US, as well as continued uptake from ongoing launches in international markets. In vaccines and infectious diseases, Gardasil sales were $2 billion, an increase of 14%. In the US, sales grew 18%, benefiting from a significant CDC purchase and price, while international markets increased 6%.

Passages & reports (12)
  • by increasing contributions
  • from our
  • compelling array of important new products and continued strength in oncology and animal h…
  • for patients, customers and shareholders. Now turning to our third quarter results. Total …
  • exchange basis. In oncology, sales of the Quetruda family of products, which includes Quet…
  • metastatic indications. Key contributors to growth included strong utilization in tumours …
  • stage head and neck cancer. As expected, the timing of US customer purchases last year cre…
  • $830 million. We continue to see adoption increase, which supports our confidence in the t…
  • In
  • our broader oncology portfolio, Welly Reg sales increased 58% to $307 million, driven by i…
  • launches in international markets. In vaccines and infectious diseases, Gardasil sales wer…
  • markets increased 6%.

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 3

Pneumococcal, Capvaxive sales were $263 million, an increase of 7%, driven by ongoing launches in certain international markets. In the US, sales declined 13% as increased market share was more than offset by lower adult pneumococcal vaccination rates. In RSV, infloncia sales of $187 million reflect seasonal demand and associated inventory build. In cardiometabolic and respiratory, WinRevair continued its momentum with global sales of $694 million, an increase of 94%, reflecting strong demand from adults with pulmonary arterial hypertension, as well as a benefit from channel inventory.

In the US, nearly 1600 new patients received a prescription, approximately 30% of whom were on background therapies that did not
include a prosperocycline. Outside the US, we continue to progress with ongoing launches. OTEVES sales were $184 million, reflecting continued demand from adults with COPD, partially offset by a small headwind from the timing of specialty pharmacy purchases. While early, we are encouraged by the initial launch of Lipfendra.

Prescription trends and physician feedback has been positive. Additionally, we have established programs to support access and affordability for eligible patients. As expected, broad
access will take time to build, and we remain confident in the long term opportunity for this important treatment option for adults with elevated LDL cholesterol. Our animal health business delivered growth of 3%. Companion animal sales increased 6%, driven by new product launches.

Livestock sales grew 2% due to higher demand for poultry products. I will now walk you through the remainder of our PL, and my comments will be on a non-GAP basis. Growth margin decreased slightly to 81.4%.

Passages & reports (7)
  • Pneumococcal, Capvaxive sales were $263 million, an increase of 7%, driven by ongoing laun…
  • vaccination rates. In RSV, infloncia sales of $187 million reflect seasonal demand and ass…
  • an increase of 94%, reflecting strong demand from adults with pulmonary arterial hypertens…
  • include a prosperocycline. Outside the US, we continue to progress with ongoing launches. …
  • purchases. While early, we are encouraged by the initial launch of Lipfendra. Prescription…
  • access will take time to build, and we remain confident in the long term opportunity for t…
  • launches. Livestock sales grew 2% due to higher demand for poultry products. I will now wa…

Operating expenses increased 12% to $7.4 billion, reflecting increased investments to support our launches and advance our diverse early and late phase pipeline. This increase was partially offset by benefits from our ongoing multi-year optimization effort and the recognition of a portion of the external funding for SAC TMT development. There was also a $400 million upfront charge related to the licence agreement with Cybranch, compared with a $300 million business development charge a year ago.

Other expense increased to $420
million, primarily reflecting financing costs related to recent business development transactions. Our tax rate was 10.9%, reflecting a benefit from certain discrete items. Taken together, earnings per share were $2.49, which includes a charge of $12 per share related to the CyberBrunch Licence Agreement. Now turning to our 2026 non-GAAP guidance. We have narrowed the range and raised the midpoint of both our full year revenue and EPS guidance.

We now expect revenue to be between
$66.8 and $67.3 billion, representing growth of 3 to 4%, including a positive impact from foreign exchange of approximately one percentage point using mid October rates. Our gross margin assumption remains approximately 81%.

Passages & reports (5)
  • Operating expenses increased 12% to $7.4 billion, reflecting increased investments to supp…
  • a portion of the external funding for SAC TMT development. There was also a $400 million u…
  • million, primarily reflecting financing costs related to recent business development trans…
  • charge of $12 per share related to the CyberBrunch Licence Agreement. Now turning to our 2…
  • $66.8 and $67.3 billion, representing growth of 3 to 4%, including a positive impact from …

Operating expenses are expected to be between 42.4 and 42.9 billion dollars. Other expense is still expected to be approximately $1.4 billion. We now expect a full year tax rate between 32 and 33%. We assume approximately 2.48 billion shares outstanding. Taken together, we expect EPS of $2.77 to $2.82, including a positive impact from foreign exchange of approximately $15 using mid-October rates. This range also includes the Psybrunch charge.

As you consider your models, there are a few items to keep in mind. Third quarter sales benefited by approximately $550 million from favorable purchase timing in the US. We expect the benefit related to Keytruder
and WinRevair to fully unwind in the fourth quarter, while the majority of the benefit to vaccines, primarily related to Gardasil, is expected to unwind next year. As we look forward to 2027, we recently noted an expectation for modest revenue growth.

For Keytruder, moderating growth reflects the success we have had in reaching the eligible patients as we now approach peak revenues for certain approved indications. Additionally, we expect the German market to be impacted by policy dynamics. For
Bridion, we expect competition from multiple generics that have now entered the market. For vaccines, we are watching broader market trends given increased hesitancy and reduced utilisation.

Finally, we also expect underlying operating expenses to
increase at a mid to high single digit rate, reflecting our conviction in the significant opportunity from our expanding pipeline and the growing portfolio of new product launches. Now turning to capital allocation, where our priorities remain unchanged. We will continue to invest in value creating opportunities that drive both near and long term growth. We remain committed to the dividend with the goal of increasing it over time.

Business development remains an important priority, and we retain financial flexibility within a strong investment
grade credit rating to pursue additional science driven value enhancing transactions. We remain on track for approximately $3 billion in share repurchases this year. To conclude, as we head into the fourth quarter, we remain confident in the outlook for our business. Demand for our diverse portfolio of human and animal health products remains strong, and our recent launches are making increasingly meaningful contributions to growth.

Our compelling innovative portfolio of pipeline assets continues to progress, leaving us very well
positioned to deliver outstanding value for patients, customers, and shareholders now and into the future. With that, I'd like to turn the call over to Dean.

Passages & reports (11)
  • Operating expenses are expected to be between 42.4 and 42.9 billion dollars. Other expense…
  • approximately 2.48 billion shares outstanding. Taken together, we expect EPS of $2.77 to $…
  • also includes the Psybrunch charge. As you consider your models, there are a few items to …
  • and WinRevair to fully unwind in the fourth quarter, while the majority of the benefit to …
  • growth. For Keytruder, moderating growth reflects the success we have had in reaching the …
  • Bridion, we expect competition from multiple generics that have now entered the market. Fo…
  • increase at a mid to high single digit rate, reflecting our conviction in the significant …
  • invest in value creating opportunities that drive both near and long term growth. We remai…
  • grade credit rating to pursue additional science driven value enhancing transactions. We r…
  • our business. Demand for our diverse portfolio of human and animal health products remains…
  • positioned to deliver outstanding value for patients, customers, and shareholders now and …

Speaker 1

Thank you,

Passages & reports (1)
  • Thank you,

Speaker unclear

?Caroline.

Passages & reports (1)
  • Caroline.

Speaker 4

Unverified voice label

Good

Passages & reports (1)
  • Good

Speaker 1

morning, everyone. The third quarter was marked by a number of significant clinical and regulatory milestones. Today I will provide updates in oncology, cardiometabolic, and respiratory, immunology and ophthalmology. I will close by highlighting upcoming milestones. Starting with oncology, as Rob noted, data from several pivotal studies were presented at ESMO, which exemplify our clinical development approach and reflect how Katruda is informing our pipeline progress.

ESMO marked the first presentation of detailed phase three findings from our expansive Clobo Trofe Fuse
Development Program for SAC

Passages & reports (3)
  • morning, everyone. The third quarter was marked by a number of significant clinical and re…
  • as Rob noted, data from several pivotal studies were presented at ESMO, which exemplify ou…
  • Development Program for SAC

Speaker 4

TMT, our Trope 2 directed ADC with a unique bifunctional linker. ?The Trove Fuse program is guided by a two prong development strategy. First,

Passages & reports (3)
  • TMT, our Trope 2 directed ADC with a unique bifunctional linker.
  • The
  • Trove Fuse program is guided by a two prong development strategy. First,

Speaker unclear

?we are moving with speed and rigor to establish early

Passages & reports (1)
  • we are moving with speed and rigor to establish early

Speaker 1

leadership in multiple disease and treatment settings. Many of these first mover opportunities are in gynecologic cancers where there remains significant unmet need. ?The Trofuse 005 study presented at ESMO evaluated SAC TMT in patients with endometrial cancer whose disease has progressed following platinum chemotherapy and anti PD1 L1 immunotherapy, demonstrating a remarkable near seven-month improvement in median overall survival compared to chemotherapy alone. Endometrial cancer is one of the few cancers with increasing incidence and mortality rates worldwide.

These patients currently face a very poor prognosis, and we look forward to continuing to work with the FDA to deliver this potential new option as
quickly as possible. Second, we are exploring the potential of SAC TMT in certain types of breast and lung cancers where we believe we can be differentiated. In first line, PDL1 negative non squamous non small cell lung cancer results from the optotrope lung O6 study conducted by our partner Keelan showed a meaningful improvement in progression free survival for SAC TMT plus Katruda over Katruda plus chemotherapy, raising the possibility that novel combinations may improve upon the high bar set by Catruda plus chemotherapy.

Our global trophuse program includes five
ongoing phase three studies in various non-small cell lung cancer settings. We plan to investigate SAC TMT in combination with MK 2010, our PD1 VEGF Bispecific in first line non-small cell lung cancer. Engagement with the FDA has been productive, and we anticipate phase three studies in this setting in the first half of 2027. Now, turning to entismeran.

Our deep understanding of tumor biology continues to inform the next generation of our oncology pipeline, including the development of an mRNA therapeutic cancer vaccine based on the unique mutational signature of
a patient's tumor. ESMOL marked the unveiling of landmark results for NTSMIRAN, an investigational individualized neoantigen therapy developed in collaboration with Moderna, ?plus Catruda as adjuvant therapy for melanoma. Results of the Interpath 001 study demonstrated clinically meaningful improvements in recurrence-free survival and distant metastases-free survival for antismeran, plus catruda over standard of care katruda in patients with completely resected stage 2B24 melanoma.

These results, building on the body of evidence from the phase 2B study, strengthen our confidence in the curative potential of intismeran when given in combination with Catruda. We are actively engaged with the FDA on
regulatory submission. Additionally, we are progressing a robust interpath clinical development program across a range of immune-sensitive tumors, including indications in earlier stages of disease where Katruda has established efficacy.

Phase three studies are ongoing in melanoma and
non-small cell lung cancer, which are characterized by high mutational burden. Ongoing phase two studies are also evaluating tumors with lower mutational burden, including certain platter and renal cancers, to inform potential future expansion. I look forward to sharing further updates on these and other oncology programs. Now to a few regulatory updates. Subcutaneous Pember Elizabeth and Barahyaluranodase Alpha was approved by regulatory authorities in Japan and China.

In Europe, we received approval for Catruda plus PATSIV as a perioperative treatment for resectable muscle
invasive bladder cancer. And in the US, the FDA approved Wellereg plus Lymvema for the treatment of patients with previously treated renal cell carcinoma. Regarding infinitomab Dirextacan, together with Daiichi Sankiol, we made the decision to withdraw the biologic license application seeking accelerated approval. Multiple studies of IDXD are ongoing in small cell lung cancer, prostate cancer, and other tumor types.

Next, in cardiometabolic and respiratory, recently the FDA approved the label update for WinRevere, incorporating results from the phase three Hyperion study, providing further
evidence to support its use earlier in the treatment journey for adults with pulmonary arterial hypertension. With WinRivere, we introduced active insignal inhibition, a novel mechanism targeting the underlying vascular remodeling that drives disease progression. Building on the findings from the phase two cadence trial, we are taking an important step to extend the application of active insignaling inhibition beyond group 1 PAH.

The upcoming phase 3 core study will evaluate patients with combined post and precapillary pulmonary hypertension associated with heart failure with preserved ejection
fraction. This distinct population within Group 2 pulmonary hypertension has similar vascular characteristics to pH and no currently approved treatment options. Next, in immunology. Last month at EADV, positive phase 2B results were presented for Tulusoka BART in patients with hydranitis superativa, making it the first anti-TO1A antibody to demonstrate positive clinical data in a dermatology indication.

The study demonstrated promising clinical responses and encouraging safety profile. Based on these findings, we plan to advance Tulasocobart into
phase three development in HS. Finally, to ophthalmology, as Rob mentioned, earlier this month, results were presented from the Phase 2B 3 Brunello study, the first of two pivotal studies evaluating RemigramIG, a novel WIMP agonist in adults with DME. Brunello achieved its primary endpoint with both doses of monthly Remigramig, demonstrating non inferior best corrected visual acuity compared to monthly 0.5 milligram rhanobismab at one year.

While anti VEGF therapies have transformed the treatment of DME, disease activity persists in many patients,
highlighting the need for new therapeutic options. Brunello provides clinical evidence that activation of the wind pathway can achieve non inferior efficacy to an anti VEGEF agent in DME. If confirmed in the companion Barolo trial, Remig Ramig could introduce a promising new and orthogonal mechanism and help advance the field of ophthalmology toward therapeutic strategies involving multiple pathways.

In closing, the breadth of these milestones reflects our progress in translating novel advances in the understanding of disease biology into potentially significant
medicines across diverse therapeutic areas. Over the next 12 months, we anticipate several important clinical and regulatory milestones, including in immunology for Tulus Oker, we are compiling data from the Phase III Atlas UC study and expect to share the results in the near term.

In ophthalmology, the readout of the Barolo study of Remigramig. In cardiometabolic and respiratory, the initiation of the phase three core study. In infectious disease, anticipated regulatory filings for Islochavir plus Lenicapavir, the potential first once-weekly Oral II drug treatment
regimen for HIV, data from the phase three anchor study evaluating MK 1406, our investigational long-acting and strain agnostic antiviral designed to prevent influenza, and the data from the phase three expressive program of our investigational once monthly oral HIV prep option, Alomatrovair.

And finally, in oncology, the potential approval of FACTMT in endometrial cancer and additional phase three readouts, the anticipated regulatory filing of anticiparan, and additional readouts in multiple other programs. And now I will turn the
call back to Peter.

Passages & reports (30)
  • leadership in multiple disease and treatment settings. Many of these first mover opportuni…
  • The
  • Trofuse 005 study presented at ESMO evaluated SAC TMT in patients with endometrial cancer …
  • survival compared to chemotherapy alone. Endometrial cancer is one of the few cancers with…
  • quickly as possible. Second, we are exploring the potential of SAC TMT in certain types of…
  • our partner Keelan showed a meaningful improvement in progression free survival for SAC TM…
  • ongoing phase three studies in various non-small cell lung cancer settings. We plan to inv…
  • studies in this setting in the first half of 2027. Now, turning to entismeran. Our deep un…
  • a patient's tumor. ESMOL marked the unveiling of landmark results for NTSMIRAN, an investi…
  • plus
  • Catruda as adjuvant therapy for melanoma. Results of the Interpath 001 study demonstrated …
  • completely resected stage 2B24 melanoma. These results, building on the body of evidence f…
  • regulatory submission. Additionally, we are progressing a robust interpath clinical develo…
  • non-small cell lung cancer, which are characterized by high mutational burden. Ongoing pha…
  • oncology programs. Now to a few regulatory updates. Subcutaneous Pember Elizabeth and Bara…
  • invasive bladder cancer. And in the US, the FDA approved Wellereg plus Lymvema for the tre…
  • approval. Multiple studies of IDXD are ongoing in small cell lung cancer, prostate cancer,…
  • evidence to support its use earlier in the treatment journey for adults with pulmonary art…
  • trial, we are taking an important step to extend the application of active insignaling inh…
  • fraction. This distinct population within Group 2 pulmonary hypertension has similar vascu…
  • Tulusoka BART in patients with hydranitis superativa, making it the first anti-TO1A antibo…
  • phase three development in HS. Finally, to ophthalmology, as Rob mentioned, earlier this m…
  • achieved its primary endpoint with both doses of monthly Remigramig, demonstrating non inf…
  • highlighting the need for new therapeutic options. Brunello provides clinical evidence tha…
  • orthogonal mechanism and help advance the field of ophthalmology toward therapeutic strate…
  • medicines across diverse therapeutic areas. Over the next 12 months, we anticipate several…
  • term. In ophthalmology, the readout of the Barolo study of Remigramig. In cardiometabolic …
  • regimen for HIV, data from the phase three anchor study evaluating MK 1406, our investigat…
  • Alomatrovair. And finally, in oncology, the potential approval of FACTMT in endometrial ca…
  • call back to Peter.

Speaker unclear

?Okay. Thanks, Dean.

Passages & reports (1)
  • Okay. Thanks, Dean.

Speaker 2

Before ?we get started

Passages & reports (3)
  • Before
  • we
  • get started

Speaker unclear

?with QA, I'm

Passages & reports (1)
  • with QA, I'm

Speaker 4

very pleased to introduce Yanni Osthazen and Brian Ford, who are with us this morning to help address questions. And as a reminder, Yanni serves as president of our oncology business unit as well as MSD International. ?And Brian serves as president of our specialty pharma and infectious diseases business unit. I'd also like to request that analysts limit themselves to a single question today so that we can get to as many different questioners as possible in the time that we ?have.

So,
Jul Julie, if you could please start the QA session. Thank

Passages & reports (5)
  • very pleased to introduce Yanni Osthazen and Brian Ford, who are with us this morning to h…
  • And
  • Brian serves as president of our specialty pharma and infectious diseases business unit. I…
  • have. So,
  • Jul Julie, if you could please start the QA session. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you. Ladies and gentlemen, if you wish to ask a question, please press on your telephone keypad. You may withdraw your question at any time by pressing star two. ?If you are using a speakerphone, please pick up the handset before pressing the numbers. Once again, if you have a question, you may press star one. One moment, please, for our first question. Our first question comes from Chris Schott with JP Morgan.

Your line is open.

Passages & reports (3)
  • Thank you. Ladies and gentlemen, if you wish to ask a question, please press on your telep…
  • If
  • you are using a speakerphone, please pick up the handset before pressing the numbers. Once…

Questions & answers

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 5

Unverified voice label

guess my question is you recently made some comments on 2027, both top line and spend. ?And uh maybe it's a two-part question. I'm just interested, do you feel that that's now appropriately reflected in consensus estimates? ?And then just given the RD spend we are seeing for the company in the near term, as well as the longer-term pipeline de-risking we've seen, is it now now fair to think about earnings growing off of this type of level as we move through the key true key true to LOE?

I guess that's
a different way. Does this RD spend effectively pull forward your trough earnings so we can think more about earnings growth from Merck as we look out to the 2030s. Thanks so

Passages & reports (6)
  • guess my question is you recently made some comments on 2027, both top line and spend.
  • And uh
  • maybe it's a two-part question. I'm just interested, do you feel that that's now appropria…
  • And
  • then just given the RD spend we are seeing for the company in the near term, as well as th…
  • a different way. Does this RD spend effectively pull forward your trough earnings so we ca…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 3

Chris, thank you for the question. First, if I can maybe provide everybody the headlines around our comments on 2027, and then I'll answer the specific questions. For 2027, we see it as another year of investment as we invest behind our expansive pipeline and our new product launches to drive long-term growth. Specifically in 2027, we expect moderate top line growth, and that's as a result of the strong contributions we expect from our new product launches as well as animal health that will be partially offset by more than two billion dollars of headwinds as a result of generic competition and LOE impacting Bridion Genuvia family of products as well as Adempus.

We do expect Keytruda to continue to be an important contributor to our overall revenues, although we do see growth
moderating, and that's as we've reached peak penetration in a number of indications. While we also expect headwinds to price in our X US market, and we are watching the policy dynamics in Germany. From a vaccines perspective, we have seen a benefit of a CDC buy in in 2026 of approximately $250 million that will unwind in 2027.

Now, as we look at the rest of the PL, growth margin will increase given the roll-off of a royalty on Keytruder. As you've noted, we expect expenses
to increase because we are fully investing behind our strong pipeline as well as our launches. And we do expect slightly higher interest expense and a slightly higher tax rate. ?But all in all, 27 marks a year of investment for strong growth in our future, which is all in part to drive our strategy of how our company grows beyond the Keytruder LOE.

Now, as we look at that, we see the Key Truder LOE
as really more of a hill on the overall revenues of our company, as we will, in short order, then return to strong growth. As we look at consensus estimates for 2027, there are a number of different estimates from the different analysts, and some have incorporated the messaging that we've given, many have not yet.

So hopefully this will provide clarity as to our expectations for 2027. And as we look at earnings as we move forward, we do expect to see our company have earnings as we move
towards the LOE period grow. We do expect, as I've noted, a shallow dip in revenues in the initial period post-the price setting through IRA and the LOE, but to quickly return to growth.

And we would expect the
earnings profile to probably mirror that given the expansive pipeline that we have and the continued studies that we will be doing and supporting, as well as the launches that are coming through year over year. So headline, confident in our future, confident in our pipeline that will drive long term growth and patient benefit and enable us to offset over time the Key Trude LOE.

Passages & reports (13)
  • Chris, thank you for the question. First, if I can maybe provide everybody the headlines a…
  • product launches to drive long-term growth. Specifically in 2027, we expect moderate top l…
  • billion dollars of headwinds as a result of generic competition and LOE impacting Bridion …
  • moderating, and that's as we've reached peak penetration in a number of indications. While…
  • CDC buy in in 2026 of approximately $250 million that will unwind in 2027. Now, as we look…
  • to increase because we are fully investing behind our strong pipeline as well as our launc…
  • But
  • all in all, 27 marks a year of investment for strong growth in our future, which is all in…
  • as really more of a hill on the overall revenues of our company, as we will, in short orde…
  • incorporated the messaging that we've given, many have not yet. So hopefully this will pro…
  • towards the LOE period grow. We do expect, as I've noted, a shallow dip in revenues in the…
  • earnings profile to probably mirror that given the expansive pipeline that we have and the…
  • pipeline that will drive long term growth and patient benefit and enable us to offset over…

Speaker unclear

?Great. Thank you,

Passages & reports (1)
  • Great. Thank you,

Speaker 4

Chris. Next question, please, Julie.

Passages & reports (1)
  • Chris. Next question, please, Julie.

Speaker 0

Thank you. Our next question comes from Bamel DeBan with Guggenheim Securities. Your line is open.

Passages & reports (1)
  • Thank you. Our next question comes from Bamel DeBan with Guggenheim Securities. Your line …

Speaker unclear

?Great, thank you

Passages & reports (1)
  • Great, thank you

Speaker 6

Unverified voice label

for taking the question and congrats on the progress ?with the pipeline. Maybe just on winter rear, if I could ask a couple. One if you ?could quickly just quantify the one time benefit you saw uh specifically for winter year this court. I know you kind of grouped it into the ?the 550 you saw overall for the farm of business. ?And then Dean, I was specifically wanted to ask you on c the chorus trial.

We did go through the listing there on the clinical You can uh discuss how it's similar or different to what we what you did with the phase two cadence trial in terms of
?the the endpoint, in terms of the inclusion criteria, just to give us a sense of how the patients and the study you're more compared to each other. Thanks.

Passages & reports (11)
  • for taking the question and congrats on the progress
  • with
  • the pipeline. Maybe just on winter rear, if I could ask a couple. One if you
  • could
  • quickly just quantify the one time benefit you saw uh specifically for winter year this co…
  • the
  • 550 you saw overall for the farm of business.
  • And
  • then Dean, I was specifically wanted to ask you on c the chorus trial. We did go through t…
  • the the
  • endpoint, in terms of the inclusion criteria, just to give us a sense of how the patients …

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 3

you, Zamel, for the question. In terms of the uh timing benefits that we saw in the quarter, if I may give the full picture, inclusive of WinRefare, so that we have it out there for all. We had a benefit in the third quarter of five hundred and fifty million dollars as a result of the timing of purchases. 200 million of that relates to Keytruder, which we will expect to unwind in full in the fourth quarter.

50 million relates to WinRevare, which we expect to unwind in the fourth quarter. A further 300 million
relates to our vaccines business, which is predominantly Gardasil. We expect 50 million to unwind in the fourth quarter, and the remaining 250 million to unwind in 2027.

Passages & reports (3)
  • you, Zamel, for the question. In terms of the uh timing benefits that we saw in the quarte…
  • of the timing of purchases. 200 million of that relates to Keytruder, which we will expect…
  • relates to our vaccines business, which is predominantly Gardasil. We expect 50 million to…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 4

Bamel, thank you very much for the questions. I'll just answer it in two parts. The first is I just want to call out for pH group one, not group two, that the field

Passages & reports (1)
  • Bamel, thank you very much for the questions. I'll just answer it in two parts. The first …

Speaker 1

is increasingly moving to a concept of with active and signaling inhibitor, the potential of remission. And you've seen that in the European guidelines that have come out, and we we're hopeful that the similar sort of standard will take. This is really

Passages & reports (1)
  • is increasingly moving to a concept of with active and signaling inhibitor, the potential …

Speaker 4

important because it suggests, similar to ACE inhibition and left heart failure, that in this right heart failure with pH group one, that physicians and the field can think differently about the treatment paradigm. The reason I want to bring that up is that what you've asked me now about group two, which is a heart failure study. We have the cadence study. Um and what we're going to be doing in the course study, and I just wanted to be pretty clear, we're we're not

Passages & reports (2)
  • important because it suggests, similar to ACE inhibition and left heart failure, that in t…
  • heart failure study. We have the cadence study. Um and what we're going to be doing in the…

Speaker 1

expanding the patient population in any substantive way. There are

Passages & reports (1)
  • expanding the patient population in any substantive way. There are

Speaker 4

details in

Passages & reports (1)
  • details in

Speaker 1

relationship to how we're gonna execute on the trial. But we really think that, quote unquote, this patient population that was seen in the cadence has an incredibly high unmet need. There's no approved treatment, it's really poor prognosis, and it's also an

Passages & reports (1)
  • relationship to how we're gonna execute on the trial. But we really think that, quote unqu…

Speaker 4

orphan indication. And so from the cadence, you know, we met primary endpoints, reduction in PVR, and important secondary endpoints. And we're gonna initiate the phase three course this year with a 0.3 milligram per kilogram dose and with time to clinical worsening in the endpoints. And we enroll we we expect that this will uh ?be a very attractive trial uh for patients with uh group two pulmonary hypertension.

Great. Thanks, Bob. Next question, please.

Passages & reports (4)
  • orphan indication. And so from the cadence, you know, we met primary endpoints, reduction …
  • expect that this will uh
  • be
  • a very attractive trial uh for patients with uh group two pulmonary hypertension. Great. T…

Speaker 0

Thank you. Our next question comes from Michael Yi with UBS. Your line is open.

Passages & reports (1)
  • Thank you. Our next question comes from Michael Yi with UBS. Your line is open.

Speaker unclear

?Great,

Passages & reports (1)
  • Great,

Speaker 7

Unverified voice label

thanks. Um maybe Dean, if I could just follow up ?on obviously the uh very busy ESMO uh conference. Maybe here you could uh offer a view

Passages & reports (3)
  • thanks. Um maybe Dean, if I could just follow up
  • on obviously the uh
  • very busy ESMO uh conference. Maybe here you could uh offer a view

Speaker unclear

?about uh the

Passages & reports (1)
  • about uh the

Speaker 6

fact that you have greater confidence in uh China studies being further replicated across all of your global trophy studies. And since I think we've discussed lung cancer enough, maybe you could just comment on where the one or two other SAC TMT indications you think are most notable ?and that you may not be paying attention to. Thank

Passages & reports (3)
  • fact that you have greater confidence in uh China studies being further replicated across …
  • and
  • that you may not be paying attention to. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 4

Okay, so

Passages & reports (1)
  • Okay, so

Speaker 1

I I had a hard time hearing, but I think the gist of your question relates to the trope two ADC that we have, our SAC TMT. And I would just highlight what was said in the in the uh remarks, which is we've always had a two part um

Passages & reports (1)
  • I I had a hard time hearing, but I think the gist of your question relates to the trope tw…

Speaker 4

strategy. Um the first part is we had recognized that when we got

Passages & reports (1)
  • strategy. Um the first part is we had recognized that when we got

Speaker 1

into this field that there were uh two uh trope twos

Passages & reports (1)
  • into this field that there were uh two uh trope twos

Speaker 4

uh that were ahead of us, but we were actually surprised that they did

Passages & reports (1)
  • uh that were ahead of us, but we were actually surprised that they did

Speaker 1

not move quickly to indications outside of breast and lung, and we thought that there

Passages & reports (1)
  • not move quickly to indications outside of breast and lung, and we thought that there

Speaker 4

would be an enormous

Passages & reports (1)
  • would be an enormous

Speaker 1

opportunity to do so. And you see that in our clinical trials as we move very fast outside of lung and breast. There are trials that we have in lung and breast, but we've moved very fast outside of that. And this most recent trophuse 005 is an evidence of that. The reason why that's important is if you look at that trophuse 005 uh as a proof point, I would just call

Passages & reports (2)
  • opportunity to do so. And you see that in our clinical trials as we move very fast outside…
  • that's important is if you look at that trophuse 005 uh as a proof point, I would just cal…

Speaker 4

your attention to, I think it was a presentation, I think in 2025 or 2026, with

Passages & reports (1)
  • your attention to, I think it was a presentation, I think in 2025 or 2026, with

Speaker 1

MK2870 001 or

Passages & reports (1)
  • MK2870 001 or

Speaker 4

Kielin 264 01. That's the phase 1 slash 2 endometrial cohort. That was the informative information for us looking at Chinese data that allowed us to figure out how to translate that in a trofe fuse 005.

Passages & reports (1)
  • Kielin 264 01. That's the phase 1 slash 2 endometrial cohort. That was the informative inf…

Speaker 1

So the bottom line is that experience working closely with Keelin, it isn't like you're going to translate them exactly, but it gives you the signal as to how you might translate it into global. So that gives us confidence that the Keelin data is a a really important uh signal for

Passages & reports (1)
  • So the bottom line is that experience working closely with Keelin, it isn't like you're go…

Speaker 4

us and that we are confident that we can

Passages & reports (1)
  • us and that we are confident that we can

Speaker 1

translate into

Passages & reports (1)
  • translate into

Speaker 4

the global trials. And we

Passages & reports (1)
  • the global trials. And we

Speaker 1

hope to replicate that in other indications outside of lung and breast. But clearly, as as Marjorie and Elliot have talked recently, we plan to go quite aggressively in loan.

Passages & reports (1)
  • hope to replicate that in other indications outside of lung and breast. But clearly, as as…

Speaker 4

Great. Thanks, Mike. Next question, please.

Passages & reports (1)
  • Great. Thanks, Mike. Next question, please.

Speaker 0

Thank you. Our next question comes from Courtney Brain with Bernstein. Your line is open.

Passages & reports (1)
  • Thank you. Our next question comes from Courtney Brain with Bernstein. Your line is open.

Speaker unclear

?Hi, Merck Team.

Passages & reports (1)
  • Hi, Merck Team.

Speaker 7

Thanks so much for taking the question today. Um I just wanted to to zoom into the subcutaneous or key true to QLEX litigation that that is ongoing around the Hylerinidase component of that product. Um we're seeing kind of obviously reports out of out of Europe and kind ?of infringement claims that are being made. Can you just contextualize where we're at in Europe relative to the US?

Is this a definitive call? Is are there likely paths to uh to moving back towards the the the launch in these European countries? And is there any risk in the US as we move forward
given uh that the path and the intentions and the litigation that is that is ongoing? Thank you so

Passages & reports (4)
  • Thanks so much for taking the question today. Um I just wanted to to zoom into the subcuta…
  • of
  • infringement claims that are being made. Can you just contextualize where we're at in Euro…
  • given uh that the path and the intentions and the litigation that is that is ongoing? Than…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Maybe maybe I'll start uh Courtney and then we'll I'll turn it over to uh to Yanni. Overall, I just w wanna emphasize we feel very strongly that we have ?uh IP that gives us freedom to operate as it relates to Culex. That's why we actually uh pursued uh uh action against uh others in the field to ensure we could do that. So uh nothing has changed to our confidence we see long term.

Uh the injunction you're seeing in Europe is just an
injunction until the the hearing is held. It doesn't speak to the merits of our belief. We continue to feel very, very good that we have a position both in the US and in Europe. But maybe I'll let uh Yanni speak specifically to the implications of Europe and how we see that potentially resolving.

Passages & reports (4)
  • Maybe maybe I'll start uh Courtney and then we'll I'll turn it over to uh to Yanni. Overal…
  • uh
  • IP that gives us freedom to operate as it relates to Culex. That's why we actually uh purs…
  • injunction until the the hearing is held. It doesn't speak to the merits of our belief. We…

Speaker 4

Yeah, thank you, Rob. And thank you for the question, Courtney. Um in relation to the US, as Rob

Passages & reports (1)
  • Yeah, thank you, Rob. And thank you for the question, Courtney. Um in relation to the US, …

Speaker unclear

?said, we feel really strong about our position in the US. And in fact, uh you

Passages & reports (1)
  • said, we feel really strong about our position in the US. And in fact, uh you

Speaker 5

saw the number eight hundred and thirty million of

Passages & reports (1)
  • saw the number eight hundred and thirty million of

Speaker 4

QLEX in the quarter or uh contribute our sub Q in the quarter, which is the majority is the US. ?Uh since we received the permanent J Code on April 1, it's really been a very positive trajectory and we feel good about the objective of getting to that 30 to 40 percent adoption in the United States by the end of 2027. So the United States, we we we're really on a good path.

In
terms of XUS, we've always talked

Passages & reports (4)
  • QLEX in the quarter or uh contribute our sub Q in the quarter, which is the majority is th…
  • Uh
  • since we received the permanent J Code on April 1, it's really been a very positive trajec…
  • terms of XUS, we've always talked

Speaker unclear

?about you know a range of uh adoption from high adoption markets to to much lower adoption. In

Passages & reports (1)
  • about you know a range of uh adoption from high adoption markets to to much lower adoption…

Speaker 1

a high

Passages & reports (1)
  • a high

Speaker unclear

?adoption market, which is the UK, Canada,

Passages & reports (1)
  • adoption market, which is the UK, Canada,

Speaker 4

Austria, uh we're actually able to supply. We're waiting for a for a for uh ?you know the launch in Canada, but these are the high adoption ?markets, and we actually see a high level of adoption in the UK already. So that is also very positive ?and not challenged by

Passages & reports (7)
  • Austria, uh we're actually able to supply. We're waiting for a for a for uh
  • you
  • know the launch in Canada, but these are the high adoption
  • markets,
  • and we actually see a high level of adoption in the UK already. So that is also very posit…
  • and
  • not challenged by

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 5

injunction out of the Netherlands.

Passages & reports (1)
  • injunction out of the Netherlands.

Speaker unclear

?In terms of Japan and China,

Passages & reports (1)
  • In terms of Japan and China,

Speaker 4

also no uh no no uh issue

Passages & reports (1)
  • also no uh no no uh issue

Speaker unclear

?from a supply and launch

Passages & reports (1)
  • from a supply and launch

Speaker 1

perspective, and we're waiting to launch in those two markets where there's significant volume and we have an ambition to uh to to get a high level of subcutaneous use. In Europe, where the where

Passages & reports (1)
  • perspective, and we're waiting to launch in those two markets where there's significant vo…

Speaker unclear

?the Dutch ruling is valid for now, as

Passages & reports (1)
  • the Dutch ruling is valid for now, as

Speaker 4

Rob said, we do not disagree with the with the Dutch court and we will continue to work to overturn this. Um so for

Passages & reports (1)
  • Rob said, we do not disagree with the with the Dutch court and we will continue to work to…

Speaker 5

now we will not

Passages & reports (1)
  • now we will not

Speaker unclear

?supply in uh in in

Passages & reports (1)
  • supply in uh in in

Speaker 5

Italy, ?Denmark, uh the Netherlands, France, Belgium, and Ireland. Uh these in general are smaller volume markers, so it's

Passages & reports (3)
  • Italy,
  • Denmark, uh the
  • Netherlands, France, Belgium, and Ireland. Uh these in general are smaller volume markers,…

Speaker 4

immaterial in terms of our overall volume of sub Q. Uh, but again, given that we have longer IP, uh if we would turn this this decision positive, we will have time to uh to get back and make this uh ?you know this convenient

Passages & reports (3)
  • immaterial in terms of our overall volume of sub Q. Uh, but again, given that we have long…
  • you
  • know this convenient

Speaker 5

formulation available to patients in these markets as well. So so overall we feel we're in a we're in a really good place in terms of subcutaneous adoption and trajectory of where we want to

Passages & reports (1)
  • formulation available to patients in these markets as well. So so overall we feel we're in…

Speaker unclear

?be.

Passages & reports (1)
  • be.

Speaker 4

Excellent. ?Thank you, Courtney. Next question, please.

Passages & reports (3)
  • Excellent.
  • Thank you,
  • Courtney. Next question, please.

Speaker 0

Thank you. ?The next question comes from Akash Tawari with Jeffries. Your line is open.

Passages & reports (3)
  • Thank you.
  • The
  • next question comes from Akash Tawari with Jeffries. Your line is open.

Speaker 1

Hey, thanks so

Passages & reports (1)
  • Hey, thanks so

Speaker unclear

?much. It looks like the primary

Passages & reports (1)
  • much. It looks like the primary

Speaker 6

endpoint for your K Ras G12C first line NACLC trial was changed from PFS and OS to PFS only back in September, which cut your target enrollment and moved up your primary completion. ?Do you think this is a part of a larger stance that maybe the FDA is taking here where hitting on OS

Passages & reports (3)
  • endpoint for your K Ras G12C first line NACLC trial was changed from PFS and OS to PFS onl…
  • Do
  • you think this is a part of a larger stance that maybe the FDA is taking here where hittin…

Speaker unclear

?is important, but not gating towards initial

Passages & reports (1)
  • is important, but not gating towards initial

Speaker 6

filing? And how could that maybe apply to the design for your first line SAC TMT PD1 VEGEF by specific trial you're aiming to start first after the next ?year? Thank

Passages & reports (3)
  • filing? And how could that maybe apply to the design for your first line SAC TMT PD1 VEGEF…
  • year?
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 4

Yeah, thank you very much for actually calling out Calderasib. I just stepped step back so that other people who are listening understand. That's our KRAS G12C inhibitor, and we think that MK1084 or culderacid is a very important molecule. It has the profile that we wish that you know any RAS molecule would have.

Passages & reports (2)
  • Yeah, thank you very much for actually calling out Calderasib. I just stepped step back so…
  • RAS molecule would have.

Speaker 1

data.

Passages & reports (1)
  • data.

Speaker 4

In relationship to our our uh moving forward in relationship to this, I think you know, part of that is uh discussions and feedback from with the FDA. I I do uh believe that all of those endpoints will be important. PFS, OS eventually will all be important. But yes, we are moving with speed uh and rigor

Passages & reports (2)
  • In relationship to our our uh moving forward in relationship to this, I think you know, pa…
  • are moving with speed uh and rigor

Speaker 1

to get this CODARACIP

Passages & reports (1)
  • to get this CODARACIP

Speaker 4

in first

Passages & reports (1)
  • in first

Speaker 1

line lung with um with Katruda,

Passages & reports (1)
  • line lung with um with Katruda,

Speaker 4

but especially especially

Passages & reports (1)
  • but especially especially

Speaker 1

sub Q Catruda moving quite fast.

Passages & reports (1)
  • sub Q Catruda moving quite fast.

Speaker 4

I should also emphasize that there

Passages & reports (1)
  • I should also emphasize that there

Speaker 1

is

Passages & reports (1)
  • is

Speaker 4

a difference of how we might have a philosophy in terms of clinical development versus others in this space. And for us, what's really important is again, this is a place where we're thinking about keynote 189, keynote 407, and asking ourselves: well, how do we displace that with those patients who have a KRAS G12C mutation,

Passages & reports (2)
  • a difference of how we might have a philosophy in terms of clinical development versus oth…
  • KRAS G12C mutation,

Speaker 1

which is

Passages & reports (1)
  • which is

Speaker 4

the dominant uh mutation uh for RAS in that patient population. And our strategy is not to add it on top of Pembroke plus chemo, but to use a Pembro plus that inhibitor by itself without the chemo, so that

Passages & reports (1)
  • the dominant uh mutation uh for RAS in that patient population. And our strategy is not to…

Speaker 1

we can create a chemo-free uh option for patients.

Passages & reports (1)
  • we can create a chemo-free uh option for patients.

Speaker 4

Great. Thanks, Nikosh. Next question, please.

Passages & reports (1)
  • Great. Thanks, Nikosh. Next question, please.

Speaker 0

Thank you. The next question comes from Dana Graybosh with Learink Partners. Your line is open.

Passages & reports (1)
  • Thank you. The next question comes from Dana Graybosh with Learink Partners. Your line is …

Speaker unclear

?I have

Passages & reports (1)
  • I have

Speaker 7

a ?follow-up that's right on RAS. You

Passages & reports (3)
  • a
  • follow-up
  • that's right on RAS. You

Speaker unclear

?have two other RAS

Passages & reports (1)
  • have two other RAS

Speaker 3

assets, one that

Passages & reports (1)
  • assets, one that

Speaker 7

you license out ?of China. I wonder if you could just step back, Dean, and talk ?about how you're thinking about ?the full portfolio across syndicat

Passages & reports (7)
  • you license out
  • of China.
  • I wonder if you could just step back, Dean, and talk
  • about how
  • you're thinking about
  • the full portfolio
  • across syndicat

Speaker 3

and combinations beyond uh caliber assets. Thank

Passages & reports (1)
  • and combinations beyond uh caliber assets. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Yeah, so uh uh uh thank you very much for that question. Um I think it shares a lot of similarities. So our interest in, ?for example, a KRAS G12D is whether we could, for example, replicate what we see in Lung with a KRAS G12D in a very similar strategy. But as I said, we're using CODORACIP and 1084 as a way to sort of measure what we do.

The other place that we have,
we think, quite good data is Kodoracib in relationship to CRC, especially in first line CRC. ?Now, in CoderasIP in CRC, KRAS G12C is a really important target, but it's it's the minority, it's it's the distinct minority of RAS mutations. KRAS G12D is the sort sort of more dominant mutation. And so our our hope is that this KRAS G12D, that we are uh we should have important clinical data in the next year or so uh will replicate what we've done in KRAS G12C in, for example, Lung and CRC.

And also, you know, we would clearly look to see what it does in pancreas. But our focus has been how do we
use culderascib and how do we look at the other isoforms of RAS or the other subtypes of RAS and how do we recreate what we believe is a really good profile for KRAS G12C and how do we replicate it for the other subtypes?

Passages & reports (8)
  • Yeah, so uh uh uh thank you very much for that question. Um I think it shares a lot of sim…
  • for
  • example, a KRAS G12D is whether we could, for example, replicate what we see in Lung with …
  • we think, quite good data is Kodoracib in relationship to CRC, especially in first line CR…
  • Now,
  • in CoderasIP in CRC, KRAS G12C is a really important target, but it's it's the minority, i…
  • G12D, that we are uh we should have important clinical data in the next year or so uh will…
  • use culderascib and how do we look at the other isoforms of RAS or the other subtypes of R…

Speaker 2

Great.

Passages & reports (1)
  • Great.

Speaker 4

Next question, please.

Passages & reports (1)
  • Next question, please.

Speaker 0

Thank you. The next question comes from Mohit Manzel with Wells Fargo. Your line is open.

Passages & reports (1)
  • Thank you. The next question comes from Mohit Manzel with Wells Fargo. Your line is open.

Speaker 5

Great.

Passages & reports (1)
  • Great.

Speaker unclear

?Thank you very much for taking my

Passages & reports (1)
  • Thank you very much for taking my

Speaker 5

question and congrats on all the progress. So just uh

Passages & reports (1)
  • question and congrats on all the progress. So just uh

Speaker unclear

?trying

Passages & reports (1)
  • trying

Speaker 6

to switch to

Passages & reports (1)
  • to switch to

Speaker 5

TL1A or Teliso, Teliso Kibart. So it does look like the field uh of IBD is moving towards combinations as we try to push remiss rates higher in earlier lines of setting. So, in that backdrop, how

Passages & reports (1)
  • TL1A or Teliso, Teliso Kibart. So it does look like the field uh of IBD is moving towards …

Speaker 6

are you thinking about building a combination strategy around TL1A? Do

Passages & reports (1)
  • are you thinking about building a combination strategy around TL1A? Do

Speaker unclear

?you think it is

Passages & reports (1)
  • you think it is

Speaker 5

strategically important to have all the complementary mechanisms in the ?house, or ?do would you be comfortable parking

Passages & reports (5)
  • strategically important to have all the complementary mechanisms in the
  • house,
  • or
  • do
  • would you be comfortable parking

Speaker unclear

?with

Passages & reports (1)
  • with

Speaker 6

uh some established market uh marketed products at this point to to find the best combination? Thank you.

Passages & reports (1)
  • uh some established market uh marketed products at this point to to find the best combinat…

Speaker 1

Yeah, so uh uh uh uh you broke up a little bit, but I'll just answer in a more general way because I think you're asking a question that's a broader question in immunology. How do you think about combinations and the such? You know, combinations have been done quite a lot in immunology. They were done back, I think, in the 2018, I can't remember, 2020 range.

And those combinations have not generally given that much benefit. So you do not see that combination strategy play out. I do have to give our credit to
a company whose more recently advanced sort of combinations, and we'll see how that data comes through. But the bottom line is combinations could be important. We believe combinations, for example, in oncology are really important. We think combinations of different mechanisms and ophthalmology is really important.

And combinations could be really important throughout immunology. However, I think each each indication and each sort of compounds that are there will have to play out and we'll have to all do as a field the work to to determine how how important and how effective
combination therapies are throughout throughout immunology and the different indications.

Passages & reports (5)
  • Yeah, so uh uh uh uh you broke up a little bit, but I'll just answer in a more general way…
  • were done back, I think, in the 2018, I can't remember, 2020 range. And those combinations…
  • a company whose more recently advanced sort of combinations, and we'll see how that data c…
  • important. And combinations could be really important throughout immunology. However, I th…
  • combination therapies are throughout throughout immunology and the different indications.

Speaker 2

And maybe I just add, because I think you had a business development angle to that question as well. So starting with, we have several assets coming through early development in-house. So we actually have a range of internal assets that could be potential combination partners, but we also remain open on the business development front, both in terms of products and development as well as commercialized products.

So we're we're looking at all fronts and uh and remain confident in that we are positioned to move depending on how we see the field evolve as Dean said.

Passages & reports (2)
  • And maybe I just add, because I think you had a business development angle to that questio…
  • front, both in terms of products and development as well as commercialized products. So we…

Speaker unclear

?Thank you,

Passages & reports (1)
  • Thank you,

Speaker 4

Moet. Next question please, Julie

Passages & reports (1)
  • Moet. Next question please, Julie

Speaker 0

Thank you. The next question comes from Steve Scala with T D Cowan. Your line is open.

Passages & reports (1)
  • Thank you. The next question comes from Steve Scala with T D Cowan. Your line is open.

Speaker unclear

?Oh

Passages & reports (1)
  • Oh

Speaker 1

thank you very much.

Passages & reports (1)
  • thank you very much.

Speaker unclear

?I'm curious what Lipfendra sales were in the quarter and what percent of prescriptions are free drug. Despite lots of competitors,

Passages & reports (1)
  • I'm curious what Lipfendra sales were in the quarter and what percent of prescriptions are…

Speaker 5

LipITOR generated ?over $800

Passages & reports (3)
  • LipITOR generated
  • over
  • $800

Speaker unclear

?million in its first year on the market. And I can't think of any reasons why Lipfendra shouldn't

Passages & reports (1)
  • million in its first year on the market. And I can't think of any reasons why Lipfendra sh…

Speaker 6

do at least that well. And I'm wondering if you agree. Thank

Passages & reports (1)
  • do at least that well. And I'm wondering if you agree. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

So appreciate the question. You know, we are, as we uh highlighted in the opening comments, as Caroline laid ?out, we are focused on affordability and access and the way we've structured this. So we are using couponing and other other means. Um, I'll let Brian speak to it. I think what you're gonna see right now is ?the script data is is quite strong. ?

Uh,
we're not gonna give specifics on on our revenue forecasts uh at the moment, but uh I'll let uh Brian get maybe give comments just so you can get a sense of how we're seeing the scripts uh evolve.

Passages & reports (7)
  • So appreciate the question. You know, we are, as we uh highlighted in the opening comments…
  • out,
  • we are focused on affordability and access and the way we've structured this. So we are us…
  • the
  • script data is is quite strong.
  • Uh,
  • we're not gonna give specifics on on our revenue forecasts uh at the moment, but uh I'll l…

Speaker unclear

?Yes,

Passages & reports (1)
  • Yes,

Speaker 4

T, thank you so much for your question. It sounds like you have uh similar excitement as we do in this particular space as well. We are seeing really early positive uptake, actually, and I'll speak to a couple of the numbers in spite of the fact that we know that this is a marketplace, but there is a significant amount of inertia. We've said that it'll be a gradual ascent as the prescriptions come in.

But I'll give you a couple of metrics to think about. So in the third quarter, we saw more than 11,000 prescriptions
?with over, and this is coming from over 6,500 prescribers. And those prescribers are broken down. We're actually seeing not just in cardiologists, but also in general practitioners, which is really encouraging. But probably what's even a little bit more encouraging than that is we're seeing then signs of that actually expanding beyond the PCSK9 marketplace.

The vast majority of prescriptions are coming from patients on other background lipid lowering therapies rather than switches off of injectable PCSK9s, which is exactly what we had had hoped for. Now keep in mind, as I think as Rob had mentioned,
?we have sampling and coupon programs that are out there today. That will affect revenue in the short term. But we're also actively in discussions with payers, and the whole goal there is to get as rapid access as possible.

Commercial, we expect, as we had mentioned before, large coverage of the access in the commercial
space in the 2027 timeframe. And then for Medicare, it's actually in the 2028 time frame as well. Now our teams are working really diligently to expedite that and bring it forward. But as we said before, you know, this is a place that there is natural inertia in the marketplace.

And so we're cautious
about the early uptake, but early signs are positive for us, and we see this again, as we said, as a meaningful growth driver for us in the future, a multi-billion opportunity.

Passages & reports (9)
  • T, thank you so much for your question. It sounds like you have uh similar excitement as w…
  • but there is a significant amount of inertia. We've said that it'll be a gradual ascent as…
  • with
  • over, and this is coming from over 6,500 prescribers. And those prescribers are broken dow…
  • The vast majority of prescriptions are coming from patients on other background lipid lowe…
  • we
  • have sampling and coupon programs that are out there today. That will affect revenue in th…
  • space in the 2027 timeframe. And then for Medicare, it's actually in the 2028 time frame a…
  • about the early uptake, but early signs are positive for us, and we see this again, as we …

Speaker unclear

?Great. Thank

Passages & reports (1)
  • Great. Thank

Speaker 2

you, Steve. Next question, please, Julie.

Passages & reports (1)
  • you, Steve. Next question, please, Julie.

Speaker 0

Thank you. ?The next question comes from Umar Raffet with Evercore ISI. Your line is open.

Passages & reports (3)
  • Thank you.
  • The
  • next question comes from Umar Raffet with Evercore ISI. Your line is open.

Speaker unclear

?Morning, guys.

Passages & reports (1)
  • Morning, guys.

Speaker 6

Thanks for taking my question. ?Dean, I was thinking ?about the recently presented melanoma data for the cancer vaccine. And my question is, how does that efficacy break down for patients that had a lower number of neo antigens?

Passages & reports (5)
  • Thanks for taking my question.
  • Dean,
  • I was thinking
  • about the
  • recently presented melanoma data for the cancer vaccine. And my question is, how does that…

Speaker unclear

?And perhaps even more importantly, patients that did not have a major driver mutation like NRAS or BRAF, et cetera. I'm

Passages & reports (1)
  • And perhaps even more importantly, patients that did not have a major driver mutation like…

Speaker 6

just trying to think through ?the implications for the upcoming RCC readout. Thank

Passages & reports (3)
  • just trying to think through
  • the
  • implications for the upcoming RCC readout. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Yeah, so um I I wanna be a little bit cautious of getting ahead of the data that was presented and the data that we are examining and will likely provide in some time, I think some people have said in the next year or so. So I I don't want to get ahead of that. But but I I would just emphasize and I if you don't mind, I'm gonna take a little bit of time here in relationship to that.

Which is
?uh you know, there was a there was a press conference that or a uh investor meeting that uh Moderna um sponsored. And I I would just call out the two really important experts that they had there, which was Georgina Long, uh who was important for this trial, and Antonio Rebus. And the reason I want to call that out is I've seen some reports about uh melanoma and all of this.

I just want to call out that Georgina Long was a senior investigator of Nadina, and Antonio Rebus was the senior author of 18 uh SWOG 1801. And
I would just quote Antonio Rebus saying this is a landmark in cancer drug development. And so we are uh eager to present that to the FDA. And I do think the data, as interpreted by those people who are scientific leaders, is that this is a landmark uh uh uh study in its own right, and because of that, we would expect that, or we would hope, I should say, that upon approval, that the NCCN guidelines would would would potentially define this as a new standard of care.

So that's the melanoma question. The other question is uh melanoma itself,

Passages & reports (7)
  • Yeah, so um I I wanna be a little bit cautious of getting ahead of the data that was prese…
  • that. But but I I would just emphasize and I if you don't mind, I'm gonna take a little bi…
  • uh
  • you know, there was a there was a press conference that or a uh investor meeting that uh M…
  • Rebus. And the reason I want to call that out is I've seen some reports about uh melanoma …
  • I would just quote Antonio Rebus saying this is a landmark in cancer drug development. And…
  • study in its own right, and because of that, we would expect that, or we would hope, I sho…

Speaker 4

you can

Passages & reports (1)
  • you can

Speaker 1

have a spectrum of TMB within melanoma, but in general the spectrum of TMB in melanoma is just shifted, it's just shifted totally in favor of being high TMB. So I would be a little bit cautious for me to re to overinterpret any data in, for example, lower TMB in melanoma as a signal for RCC. I think the fundamental issue is that what you've seen is that, at least in our hands, uh checkpoint inhibitors and I.O.

agents, not just ours, but for example, IL2, have worked, you know, that's that has been, you know, a place that uh RCC
has been a good tumor in relationship to what you would call immunoresponsive. And you know, I I think TMB is important, but I also think TMB is not the only, only determinant of immune responsiveness. And if you take that view, that's how I look at our upcoming uh study with RCC.

I'm not so sure that
?uh parsing the TMB within melanoma will give me any increased or decreased confidence in relationship to RCC.

Passages & reports (6)
  • have a spectrum of TMB within melanoma, but in general the spectrum of TMB in melanoma is …
  • in melanoma as a signal for RCC. I think the fundamental issue is that what you've seen is…
  • has been a good tumor in relationship to what you would call immunoresponsive. And you kno…
  • our upcoming uh study with RCC. I'm not so sure that
  • uh
  • parsing the TMB within melanoma will give me any increased or decreased confidence in rela…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 4

you, Umar. Next question, please.

Passages & reports (1)
  • you, Umar. Next question, please.

Speaker 0

Thank you. The next question comes from Asad Hayder with Goldman Sachs. Your line is open.

Passages & reports (1)
  • Thank you. The next question comes from Asad Hayder with Goldman Sachs. Your line is open.

Speaker 4

Great.

Passages & reports (1)
  • Great.

Speaker unclear

?Thanks for taking the question. Um, a lot of mine have been asked,

Passages & reports (1)
  • Thanks for taking the question. Um, a lot of mine have been asked,

Speaker 6

but maybe one big picture zooming out for you, Rob. Uh just, you know, given the developments over the course of this year, would be great to get any updated framing on how you see the seventy billion dollar revenue opportunity you've talked about by the mid-2030s. You've obviously had a lot of pipeline success over the course of the year. The company continues to transform its Things are moving in the right direction to de-risk that number. ?

So
maybe just double click on the pushes and pulls that have occurred to

Passages & reports (4)
  • but maybe one big picture zooming out for you, Rob. Uh just, you know, given the developme…
  • over the course of the year. The company continues to transform its Things are moving in t…
  • So
  • maybe just double click on the pushes and pulls that have occurred to

Speaker 5

influence that

Passages & reports (1)
  • influence that

Speaker 6

and

Passages & reports (1)
  • and

Speaker 5

remind us on what wasn't incorporated into that framing and what surprised you to the positive side and what's still

Passages & reports (1)
  • remind us on what wasn't incorporated into that framing and what surprised you to the posi…

Speaker 6

underappreciated. Thank

Passages & reports (1)
  • underappreciated. Thank

Speaker unclear

?you. Yeah,

Passages & reports (1)
  • you. Yeah,

Speaker 2

no, I appreciate that. So you know overall my the pride I have in what we've done as a company and how we're moving forward, given the fact that we've seen uh so much of our clinical uh data read out positive to date, you know, obviously these are studies, so you you every card's a new card and you have to wait to see the until the next card's overturned.

But that said, what we've seen so far gives me great confidence and increased confidence in that $70 billion. And as such, as we've indicated, we expect now to be raising that number, not only because what we're seeing
confidence in what we have, but what wasn't included, which is I think part of your question. And I would just remind you that when we gave that number, we did not have the turns uh acquisition included.

That is going to be addition to that number. In addition to that, we really put nothing
in for for the PD one BEG F, which now, given what you've heard uh coming out ?of several different um conferences and other meetings, we have growing confidence in that as a combination agent uh for us as we think about that with SAC TMT uh and with with everything else.

So so a lot of excitement there. SAC TMT itself is probably going to have broader indications as we look forward
with given the fact that we're kicking off new studies there as well. And then lastly and importantly, in Tismeron, you know, we had uh in TISMRON was in our initial expectation, but it was based on a product profile that, frankly, given the data we have seen, ?uh, we actually see a better commercial profile than what we expected.

So the tar the targeted product profile now is stronger. And so that in and of itself would drive some upside. So as we look across the portfolio, um, I feel very good about uh where we are and our ability to navigate the
Catruda LOE. And importantly, we have a lot more catalysts coming uh as you look out over the next twelve to twenty-four months.

So I
?think um we need to continue to see those cards, but I I feel very good about where we're sitting right

Passages & reports (12)
  • no, I appreciate that. So you know overall my the pride I have in what we've done as a com…
  • a new card and you have to wait to see the until the next card's overturned. But that said…
  • confidence in what we have, but what wasn't included, which is I think part of your questi…
  • in for for the PD one BEG F, which now, given what you've heard uh coming out
  • of
  • several different um conferences and other meetings, we have growing confidence in that as…
  • with given the fact that we're kicking off new studies there as well. And then lastly and …
  • uh,
  • we actually see a better commercial profile than what we expected. So the tar the targeted…
  • Catruda LOE. And importantly, we have a lot more catalysts coming uh as you look out over …
  • think
  • um we need to continue to see those cards, but I I feel very good about where we're sittin…

Speaker unclear

?now.

Passages & reports (1)
  • now.

Speaker 4

Great. Thank you, Asad. Next question, please.

Passages & reports (1)
  • Great. Thank you, Asad. Next question, please.

Speaker 0

Thank you. The next question comes from Terrence Flynn with Morgan Stanley. Your line is open.

Passages & reports (1)
  • Thank you. The next question comes from Terrence Flynn with Morgan Stanley. Your line is o…

Speaker 5

Great. Uh thanks for taking the question. Um maybe a follow-up to a prior one. Dean, I recognize your comments on melanoma and what it means for other tumor types. What about the implications of the INT PDAC poster that were presented at ESMO? We could just help for put it that con into context for us and the the importance of that as you think about other tumor types.

Thank

Passages & reports (2)
  • Great. Uh thanks for taking the question. Um maybe a follow-up to a prior one. Dean, I rec…
  • for us and the the importance of that as you think about other tumor types. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Yeah, so um ?uh I did not enjoy the the balmy weather in Spain, uh, and I had Eli of and uh Marjorie out there, but I listened very carefully to some of the questions that were placed before them and also to our Moderna colleagues. So I I will just answer just in a more broad way. We we have like four phase three interpaths and we have five phase twos.

There is a strategy to broaden it from melanoma to lung to bladder to RCC within the conservative point of view in relationship of where we know immune
that those are immune responsive and specifically our checkpoint inhibitor responsive and specifically our Catruda responsive and specifically Catruda responsive in early stage. When you look at our trials, I think it's very important because people have asked different questions.

And I I I'll get to your pancreatic study,
?but we have laid it out that what could it do without an IO agent? And so you see in stage one, non-small cell lung cancer in interpath 14, that's what we're doing. In NMIBC, we're asking in the absence of checkpoint inhibitor. We're asking what happens in metastatic, that's first line melanoma, that's uh interpath O12, and first line squamous non-small cell lung cancer, interpath O3 uh O13.

Specifically, your question of something that's IO-nonresponsive, that's not where we've placed most of our phase three, phase two, but there are data from our uh other people moving uh field
that suggests that we should look at it. And that's a we're testing whether or not with a checkpoint inhibitor or even IO non-responsive tumors, we'll how to think about it. But I also just want to make sure that everyone understands that there were questions in relationship to perioperative and all of this for melanoma.

We also have questions of perioperative. We're not asking that question so much in melanoma, but we're asking that in non-small cell lung cancer, which is intrapath 009. So I just want to give a sense that some of the questions that were asked that I've seen, we don't have every trial, but I
hope that gives you a general sense of we have melanoma and we're trying to broaden the scope and we're trying to do the experiments that will teach us not just what tumor type, but how to think about the indication and the mechanism of action.

Passages & reports (11)
  • Yeah, so um
  • uh
  • I did not enjoy the the balmy weather in Spain, uh, and I had Eli of and uh Marjorie out t…
  • broad way. We we have like four phase three interpaths and we have five phase twos. There …
  • that those are immune responsive and specifically our checkpoint inhibitor responsive and …
  • but
  • we have laid it out that what could it do without an IO agent? And so you see in stage one…
  • O12, and first line squamous non-small cell lung cancer, interpath O3 uh O13. Specifically…
  • that suggests that we should look at it. And that's a we're testing whether or not with a …
  • melanoma. We also have questions of perioperative. We're not asking that question so much …
  • hope that gives you a general sense of we have melanoma and we're trying to broaden the sc…

Speaker 4

Great. Thank you, Terrence. And we know it's a busy day for all of you, and we're at the top of the hour, so we're going to end it there. Thank you all for the very good questions and please follow up with the IR team for any follow-ups.

Passages & reports (1)
  • Great. Thank you, Terrence. And we know it's a busy day for all of you, and we're at the t…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 306. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T22:25:53.406Z.
Transcript version v1-85f7dee0abc55789809e · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.